The use of medications in the secondary prevention of coronary artery disease in the Asian region

References

• Kim AS, Johnston SC. Global variation in the relative burden of stroke and ischemic heart disease. Circulation 2011;124:314-23
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global atlas on cardiovascular disease prevention and control 2011. Available at: http://www.who.int/cardiovascular_diseases/publications/atlas_cvd/en/ [Last accessed 30 September 2013]
   Google Scholar
• Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006;3:e442
   PubMed Web of Science ®Google Scholar
• Sasayama S. Heart disease in Asia. Circulation 2008;118:2669-71
   PubMed Web of Science ®Google Scholar
• Khor GL. Cardiovascular epidemiology in the Asia-Pacific region. Asia Pac J Clin Nutr 2001;10:76-80
   PubMed Web of Science ®Google Scholar
• Ueshima H, Sekikawa A, Miura K, et al. Cardiovascular disease and risk factors in Asia: a selected review. Circulation 2008;118:2702-9
   PubMed Web of Science ®Google Scholar
• Kannel WB, Larson M. Long-term epidemiologic prediction of coronary disease. The Framingham experience. Cardiology 1993;82:137-52
   PubMed Web of Science ®Google Scholar
• Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case–control study. Lancet 2004;364:937-52
   PubMed Web of Science ®Google Scholar
• O’Donnell MJ, Xavier D, Liu L, et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case–control study. Lancet 2010;376:112-23
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Steg PG, Ohman EM, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006;295:180-9
   PubMed Web of Science ®Google Scholar
• Yusuf S, Islam S, Chow CK, et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE study): a prospective epidemiological survey. Lancet 2011;378:1231-43
   PubMed Web of Science ®Google Scholar
• Qaseem A, Fihn SD, Dallas P, et al. Management of stable ischemic heart disease: summary of a clinical practice guideline from the American College of Physicians/American College of Cardiology Foundation/American Heart Association/American Association for Thoracic Surgery/Preventive Cardiovascular Nurses Association/Society of Thoracic Surgeons. Ann Intern Med 2012;157:735-43
   PubMed Web of Science ®Google Scholar
• Fihn SD, Gardin JM, Abrams J, et al. Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2012;60:e44-164
   PubMed Web of Science ®Google Scholar
• Perk J, De Backer G, Gohlke H, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The fifth joint task force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur J Prev Cardiol 2012;19:585-667
   PubMed Web of Science ®Google Scholar
• Montalescot G, Sechtem U, Achenbach S, et al. For The Task Force on the management of stable coronary artery disease of the European Society of Cardiology. 2013 ESC guidelines on the management of stable coronary artery disease. Eur Heart J 2013;34:2949-3003
   PubMed Web of Science ®Google Scholar
• Simpson E, Beck C, Richard H, et al. Drug prescriptions after acute myocardial infarction: dosage, compliance, and persistence. Am Heart J 2003;145:438-44
   PubMed Web of Science ®Google Scholar
• Ege MR, Guray U, Guray Y, et al. Acute heart failure with accompanying chronic obstructive pulmonary disease: should we focus on beta blockers? Herz 2012;37:796-800
   PubMed Web of Science ®Google Scholar
• Pascual-Figal DA, Redondo B, Caro C, et al. Comparison of late mortality in hospitalized patients >70 years of age with systolic heart failure receiving beta blockers versus those not receiving beta blockers. Am J Cardiol 2008;102:1711-17
   PubMed Web of Science ®Google Scholar
• De Ferrari GM, Leonardi S, Baduena L, et al. Patients with acute coronary syndrome and nonobstructive coronary artery disease in the real world are markedly undertreated. J Cardiovasc Med (Hagerstown) 2011;12:700-8
   PubMed Web of Science ®Google Scholar
• Robinson JG, Maheshwari N. A ‘poly-portfolio’ for secondary prevention: a strategy to reduce subsequent events by up to 97% over five years. Am J Cardiol 2005;95:373-8
   PubMed Web of Science ®Google Scholar
• Colucci WS. Landmark study: the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction Study (CAPRICORN). Am J Cardiol 2004;93:13B-16B
   Google Scholar
• Youn YJ, Yoo BS, Lee JW, et al. Treatment performance measures affect clinical outcomes in patients with acute systolic heart failure: report from the Korean Heart Failure Registry. Circ J 2012;76:1151-8
   PubMed Web of Science ®Google Scholar
• Lee JH, Yang DH, Park HS, et al. Suboptimal use of evidence-based medical therapy in patients with acute myocardial infarction from the Korea Acute Myocardial Infarction Registry: prescription rate, predictors, and prognostic value. Am Heart J 2010;159:1012-19
   PubMed Web of Science ®Google Scholar
• Chin SP, Sapari S, How SH, Sim KH. Managing congestive heart failure in a general hospital in Malaysia. Are we keeping pace with evidence? Med J Malaysia 2006;61:278-83
   PubMedGoogle Scholar
• World Data Table. Available at: http://www.who.int/cardiovascular_diseases/en/cvd_atlas_29_world_data_table.pdf [Last accessed 30 September 2013]
   Google Scholar
• Zhao FH, Chen YD, Song XT, et al. Predictive factors of recurrent angina after acute coronary syndrome: the global registry acute coronary events from China (Sino-GRACE). Chin Med J 2008;121:12-16
   PubMed Web of Science ®Google Scholar
• Irani PM, Dalal J, Parikh K, et al. Multicentre retrospective study to understand anti-thrombotic treatment patterns and outcomes of acute coronary syndrome (ACS) patients (TRACE). Available at: http://clinicaltrials.gov/ct2/show/NCT01280630?term=NCT01280630&rank=1 [Last accessed 30 September 2013]
   Google Scholar
• Xavier D, Pais P, Devereaux PJ, et al. Treatment and outcomes of acute coronary syndromes in India (CREATE): a prospective analysis of registry data. Lancet 2008;371:1435-42
   PubMed Web of Science ®Google Scholar
• Dharma S, Juzar DA, Firdaus I, et al. Acute myocardial infarction system of care in the third world. Neth Heart J 2012;20:254-9
   PubMed Web of Science ®Google Scholar
• Chin SP, Jeyaindran S, Azhari R, et al. Acute coronary syndrome (ACS) registry – leading the charge for National Cardiovascular Disease (NCVD) Database. Med J Malaysia 2008;63(Suppl C):29-36
   PubMedGoogle Scholar
• Yaneza LO, Abanilla JM, Abola MTB, et al. Philippine Heart Association-Acute Coronary Syndrome Registry-2 year results. Philippine J Cardiol 2013;41:59-65
   Google Scholar
• Singapore myocardial infarction registry report no. 1. Trends in acute myocardial infarction in Singapore 2007–2010. Ministry of Health, Singapore. Available at: http://www.nrdo.gov.sg/uploadedFiles/NRDO/Publications/AMI_16.pdf [Last accessed 30 September 2013]
   Google Scholar
• Srimahachota S, Boonyaratavej S, Kanjanavanit R, et al. Thai Registry in Acute Coronary Syndrome (TRACS) – an extension of Thai Acute Coronary Syndrome registry (TACS) group: lower in-hospital but still high mortality at one-year. J Med Assoc Thai 2012;95:508-18
   PubMedGoogle Scholar
• Li J, Chen Y, Li X, et al. Use of secondary preventive medications in patients with atherosclerotic disease in urban China: a cross-sectional study of 16,860 patients. Chin Med J (Engl) 2012;125:4361-7
   PubMed Web of Science ®Google Scholar
• Yan B, Liu M, Huang XR, et al. Adherence to STEMI and NSTEMI management guidelines and clinical outcomes: a single center experience in Hong Kong. Eur Heart J 2012;14(Suppl A):P054
   Google Scholar
• Sharma KK, Gupta R, Agrawal A, et al. Low use of statins and other coronary secondary prevention therapies in primary and secondary care in India. Vasc Health Risk Manag 2009;5:1007-14
   PubMedGoogle Scholar
• Meadows TA, Bhatt DL, Cannon CP, et al. Ethnic differences in cardiovascular risks and mortality in atherothrombotic disease: insights from the REduction of Atherothrombosis for Continued Health (REACH) registry. Mayo Clin Proc 2011;86:960-7
   PubMed Web of Science ®Google Scholar
• Boden WE. Management of chronic coronary disease: is the pendulum returning to equipoise? Am J Cardiol 2008;101:69-74D
   PubMedGoogle Scholar
• Kones R. Recent advances in the management of chronic stable angina II. Anti-ischemic therapy, options for refractory angina, risk factor reduction, and revascularization. Vasc Health Risk Manag 2010;6:749-74
   PubMedGoogle Scholar
• Pflieger M, Winslow BT, Mills K, Dauber IM. Medical management of stable coronary artery disease. Am Fam Physician 2011;83:819-26
   PubMed Web of Science ®Google Scholar
• Jonsson G, Abdelnoor M, Seljeflot I, et al. The antioxidative effects of long-term treatment are more pronounced for carvedilol than for atenolol in post-myocardial infarction patients. J Cardiovasc Pharmacol 2007;49:27-32
   PubMed Web of Science ®Google Scholar
• Chin BSP, Langford NJ, Nuttall SL, et al. Anti-oxidative properties of beta-blockers and angiotensin-converting enzyme inhibitors in congestive heart failure. Eur J Heart Fail 2003;5:171-4
   PubMed Web of Science ®Google Scholar
• Kukin ML, Kalman J, Charney RH, et al. Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure. Circulation 1999;99:2645-51
   PubMed Web of Science ®Google Scholar
• Nishio M, Sakata Y, Mano T, et al. Beneficial effects of bisoprolol on the survival of hypertensive diastolic heart failure model rats. Eur J Heart Fail 2008;10:446-53
   PubMed Web of Science ®Google Scholar
• Riva N, Lip GY. Nebivolol for the treatment of heart failure. Expert Opin Investig Drugs 2011;20:1733-46
   PubMed Web of Science ®Google Scholar
• Sezai A, Nakai T, Hata M, et al. Feasibility of landiolol and bisoprolol for prevention of atrial fibrillation after coronary artery bypass grafting: a pilot study. J Thorac Cardiovasc Surg 2012;144:1241-8
   PubMed Web of Science ®Google Scholar
• Bristow MR, Feldman AM, Kirkwood FA, Goldstein S. Selective versus nonselective β-blockade for heart failure therapy: are there lessons to be learned from the COMET trial? J Card Fail 2003;9:444-53
   PubMed Web of Science ®Google Scholar
• Communal C, Singh K, Sawyer DB, Colucci WS. Opposing effects of beta-1 and beta-2 adrenergic receptors on cardiac myocyte apoptosis. Circulation 1999;100:2210-12
   PubMed Web of Science ®Google Scholar
• Chinese Society of Cardiology of Chinese Medical Association, Editorial Board of Chinese Journal of Cardiology. Chinese guidelines for prevention of cardiovascular diseases. Zhonghua Xin Xue Guan Bing Za Zhi 2011;39:3-22
   PubMedGoogle Scholar
• Indonesian Heart Association. Available at: http://www.inaheart.org [Last accessed 2 December 2013]
   Google Scholar
• Malaysian Ministry of Health. Clinical practice guideline on unstable angina/NSTEMI. June 2011. MOH/P/PAK/219.11(GU). Available at: http://www.malaysiaheart.org [Last accessed 30 September 2013]
   Google Scholar
• Philippine Heart Association Clinical Practice Guidelines for the Management of Coronary Artery Disease, 2008. Available at: http://www.philheart.org/documents/CAD_PHAguidelines2_rev26.pdf [Last accessed 30 September 2013]
   Google Scholar
• Association of Physicians of India. API expert consensus document on management of ischemic heart disease. J Assoc Physicians India 2006;54:469-80
   PubMedGoogle Scholar
• Jneid H, Anderson JL, Wright RS, et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2012;60:645-81
   PubMed Web of Science ®Google Scholar
• Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 2007;50:e1-157
   PubMed Web of Science ®Google Scholar
• Crowe E, Lovibond K, Gray H, et al. Early management of unstable angina and non-ST segment elevation myocardial infarction: summary of NICE guidance. BMJ 2010;340:c1134
   Google Scholar
• British Cardiac Society Guidelines and Medical Practice Committee and Royal College of Physicians Clinical Effectiveness and Evaluation Unit. Heart 2001;85:133-42
   Google Scholar
• Casella G, Greco C, Maggioni AP, Di Pasquale G. Secondary prevention of acute coronary syndromes: are we following correctly the guidelines? [Article in Italian.] G Ital Cardiol (Rome) 2006;7:176-85
   PubMedGoogle Scholar
• Sabouret P, Asseman P, Dallongeville J, et al. Observational study of adherence to European clinical practice guidelines for the management of acute coronary syndrome in revascularized versus non-revascularized patients – the CONNECT study. Arch Cardiovasc Dis 2010;103:437-46
   PubMedGoogle Scholar
• Pedone C, Di Pasquale G, Greco C, et al. Prescription at discharge of recommended treatments for secondary prevention in patients with ST-segment elevation myocardial infarction according to reperfusion strategies. Results from the IN-ACS outcome study. Acute Card Care 2009;11:222-8
   PubMedGoogle Scholar
• Bagnall AJ, Yan AT, Yan RT, et al. Optimal medical therapy for non-ST-segment-elevation acute coronary syndromes: exploring why physicians do not prescribe evidence-based treatment and why patients discontinue medications after discharge. Circ Cardiovasc Qual Outcomes 2010;3:530-7
   PubMed Web of Science ®Google Scholar
• Gupta R. Secondary prevention of coronary artery disease in urban Indian primary care. Int J Cardiol 2009;135:184-6
   PubMed Web of Science ®Google Scholar
• Turley AJ, Roberts AP, Morley R, et al. Secondary prevention following coronary artery bypass grafting has improved but remains sub-optimal: the need for targeted follow-up. Interact Cardiovasc Thorac Surg 2008;7:231-4
   PubMedGoogle Scholar
• Coveney AP, O’Brien GC, Fulton GJ. ACE up the sleeve – are vascular patients medically optimized? Vasc Health Risk Manag 2011;7:15-21
   PubMedGoogle Scholar
• Ferrari R, Fox K. Insight into the mode of action of ACE inhibition in coronary artery disease: the ultimate ‘EUROPA’ story. Drugs 2009;69:265-77
   PubMed Web of Science ®Google Scholar
• Vardeny O, Uno H, Braunwald E, et al. Opposing effects of β blockers and angiotensin-converting enzyme inhibitors on development of new-onset diabetes mellitus in patients with stable coronary artery disease. Am J Cardiol 2011;107:1705-9
   PubMed Web of Science ®Google Scholar
• Köhler GI, Bode-Böger SM, Busse R, et al. Drug–drug interactions in medical patients: effects of in-hospital treatment and relation to multiple drug use. Int J Clin Pharmacol Ther 2000;38:504-13
   PubMed Web of Science ®Google Scholar
• Gotsman I, Rubonivich S, Azaz-Livshits T. Use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure: an observational study of treatment rates and clinical outcome. Isr Med Assoc J 2008;10:214-18
   PubMed Web of Science ®Google Scholar
• Lopez-Sendon J, Swedberg K, McMurray J, et al. Expert consensus document on beta-adrenergic receptor blockers. Eur Heart J 2004;25:1341-62
   PubMed Web of Science ®Google Scholar
• Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009;338:b1665
   PubMed Web of Science ®Google Scholar
• Freemantle N, Cleland J, Young P, et al. Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999;318:1730-7
   PubMed Web of Science ®Google Scholar
• Cruickshank JM. Are we misunderstanding beta-blockers. Int J Cardiol 2007;120:10-27
   PubMed Web of Science ®Google Scholar
• Maio V, Marino M, Robeson M, Gagne JJ. Beta-blocker initiation and adherence after hospitalisation for acute myocardial infarction. Eur J Cardiovasc Prev Rehabil 2011;18:438-45
   PubMed Web of Science ®Google Scholar
• Barron AJ, Zaman N, Cole GD, et al. Systematic review of genuine versus spurious side-effects of beta-blockers in heart failure using placebo control: Recommendations for patient information. Int J Cardiol 2013;168:3572-9
   PubMed Web of Science ®Google Scholar
• Rutten FH, Zuithoff NP, Hak E, et al. Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med 2010;170:880-7
   PubMed Web of Science ®Google Scholar
• Etminan M, Jafari S, Carleton B, FitzGerald JM. Beta-blocker use and COPD mortality: a systematic review and meta-analysis. BMC Pulm Med 2012;12:48
   PubMedGoogle Scholar
• Olenchock BA, Fonarow GG, Pan W, et al. Current use of beta blockers in patients with reactive airway disease who are hospitalized with acute coronary syndromes. Am J Cardiol 2009;103:295-300
   PubMed Web of Science ®Google Scholar
• Ranasinghe I, Alprandi-Costa B, Chow V, et al. Risk stratification in the setting of non-ST elevation acute coronary syndromes 1999–2007. Am J Cardiol 2011;108:617-24
   PubMed Web of Science ®Google Scholar
• Melloni C, Alexander KP, Ou FS, et al. Predictors of early discontinuation of evidence-based medicine after acute coronary syndrome. Am J Cardiol 2009;104:175-81
   PubMed Web of Science ®Google Scholar